These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36629124)

  • 21. The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer.
    Alexander PG; Matly AAM; Jirapongwattana N; Pennel KAF; van Wyk HC; McMillan DC; Horgan PG; Roxburgh CSD; Thuwajit C; Roseweir AK; Quinn J; Park JH; Edwards J
    Hum Pathol; 2022 Sep; 127():1-11. PubMed ID: 35623467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
    Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
    Liu Z; Guo C; Dang Q; Wang L; Liu L; Weng S; Xu H; Lu T; Sun Z; Han X
    EBioMedicine; 2022 Jan; 75():103750. PubMed ID: 34922323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
    Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
    Front Immunol; 2021; 12():805883. PubMed ID: 35095892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel epithelial-mesenchymal transition molecular signature predicts the oncological outcomes in colorectal cancer.
    Shan Z; Wu W; Yan X; Yang Y; Luo D; Liu Q; Li X; Goel A; Ma Y
    J Cell Mol Med; 2021 Apr; 25(7):3194-3204. PubMed ID: 33660944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.
    O'Cathail SM; Wu CH; Lewis A; Holmes C; Hawkins MA; Maughan T
    Cancer Genet; 2020 Oct; 248-249():1-10. PubMed ID: 32871287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma.
    Shi Y; Wang J; Huang G; Zhu J; Jian H; Xia G; Wei Q; Li Y; Yu H
    Hepatol Int; 2022 Aug; 16(4):906-917. PubMed ID: 35699863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer.
    Liu J; Yu F; Liu Z; Wang X; Li J
    Cancer Biother Radiopharm; 2022 Dec; 37(10):963-975. PubMed ID: 34551265
    [No Abstract]   [Full Text] [Related]  

  • 29. B7-H4 is a potential diagnostic and prognostic biomarker in colorectal cancer and correlates with the epithelial-mesenchymal transition.
    Yan X; Hong B; Feng J; Jin Y; Chen M; Li F; Qian Y
    BMC Cancer; 2022 Oct; 22(1):1053. PubMed ID: 36217128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature.
    Nallandhighal S; Vince R; Karim R; Groves S; Stangl-Kremser J; Russell C; Hu K; Pham T; Cani AK; Liu CJ; Zaslavsky A; Mehra R; Cieslik M; Morgan TM; Palapattu GS; Udager AM; Salami SS
    Eur Urol Oncol; 2022 Feb; 5(1):92-99. PubMed ID: 34840106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
    Robles J; Pintado-Berninches L; Boukich I; Escudero B; de Los Rios V; Bartolomé RA; Jaén M; Martín-Regalado Á; Fernandez-Aceñero MJ; Imbaud JI; Casal JI
    J Pathol Clin Res; 2022 Nov; 8(6):495-508. PubMed ID: 36134447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma.
    Shi Y; Li Z; Zhou Z; Liao S; Wu Z; Li J; Yin J; Wang M; Weng M
    PeerJ; 2022; 10():e12646. PubMed ID: 35116193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
    Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer.
    Lu Y; Wang W; Liu Z; Ma J; Zhou X; Fu W
    Mol Med; 2021 Aug; 27(1):83. PubMed ID: 34344319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients.
    Pichler M; Ress AL; Winter E; Stiegelbauer V; Karbiener M; Schwarzenbacher D; Scheideler M; Ivan C; Jahn SW; Kiesslich T; Gerger A; Bauernhofer T; Calin GA; Hoefler G
    Br J Cancer; 2014 Mar; 110(6):1614-21. PubMed ID: 24504363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
    Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
    Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-Cell RNA Sequencing Reveals the Role of Epithelial Cell Marker Genes in Predicting the Prognosis of Colorectal Cancer Patients.
    Shen KY; Chen BY; Gao WC
    Dis Markers; 2022; 2022():8347125. PubMed ID: 35968507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a hypoxia-related gene prognostic signature in colorectal cancer based on bulk and single-cell RNA-seq.
    Qiao Y; Jiang X; Li Y; Wang K; Chen R; Liu J; Du Y; Sun L; Li J
    Sci Rep; 2023 Feb; 13(1):2503. PubMed ID: 36781976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.